# Correction: First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: study protocol for a prospective, multicenter, phase II study

**Authors:** Xiaofen Li, Qing Ma, Chen Chang, Hao Li, Dan Cao

PMC · DOI: 10.3389/fonc.2026.1726750 · Frontiers in Oncology · 2026-03-02

## Full-text entities

- **Diseases:** gastroenteropancreatic neuroendocrine carcinoma (MESH:C535650)
- **Chemicals:** camrelizumab (MESH:C000631724)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12990182/full.md

---
Source: https://tomesphere.com/paper/PMC12990182